Researchers this week are exploring bold new drug combinations, and an AI system found a 7-drug mix that could keep lung strength near normal levels — offering real hope for people living with IPF (a condition where lung tissue gradually scars and stiffens).
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
This week, the IPF research community is buzzing with over 2,250 studies in the pipeline and 755 active clinical trials (real-world tests of new treatments on volunteers). Most of the latest papers covered in our database focus on lung-related conditions, with scientists around the world — especially in Russia, China, and Korea — sharing new findings. While none of this week's newest papers were directly about IPF, the broader work on lung function and airway disease keeps moving the science forward for everyone with a scarring lung condition.
An AI system tested hundreds of drug combinations to see which best protected lung capacity. The winner used 7 drugs together — including pamrevlumab (a drug that fights scarring) and inhaled FGF10 (a growth factor that helps repair lung tissue) — and reached an FVC (a measure of how much air your lungs can hold) of 93.6%. For context, a healthy FVC is around 100%, so 93.6% is remarkably close to normal.
One question to ask your lung doctor at your next visit: "Are there any clinical trials combining anti-scarring drugs like pamrevlumab with lung-repair treatments that I might be eligible to join?"